Current Computational Approaches for the Discovery of Novel Anticancer Agents Targeting VEGFR and SIRT Signaling...

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Genetic and epigenetic factors are crucial in cancer development and progression.
• Vascular Endothelial Growth Factor Receptor (VEGFR) and epigenetic signaling pathways are implicated in cancer pathophysiology.
• Sirtuins are key epigenetic factors involved in cancer development.

Purpose of the Study:

• To review novel therapeutic agents targeting VEGFR and epigenetic pathways in carcinogenesis.
• To explore the potential of dual inhibitors targeting both VEGFR and epigenetic factors for personalized cancer therapy.
• To examine the anticancer mechanisms of VEGFR, sirtuin, and dual-target inhibitors.

Main Methods:

• Literature review of scientific studies on cancer molecular mechanisms.
• Analysis of Computer-Aided Drug Design (CADD) approaches for novel inhibitor development.
• Exploration of therapeutic strategies involving dual inhibition of VEGFR and epigenetic factors.

Main Results:

• VEGFR and epigenetic pathways significantly contribute to cancer's complex changes.
• Simultaneous targeting of VEGFR and sirtuins via dual inhibitors offers potential for individualized, safer, and more effective cancer treatments.
• CADD facilitates the design of novel chemotypes for dual-target inhibitors, accelerating drug discovery.

Conclusions:

• Dual inhibitors targeting VEGFR and epigenetic factors represent a promising avenue for innovative cancer therapies.
• CADD is a valuable tool for designing novel epigenetic dual-target inhibitors.
• Understanding the anticancer mechanisms of these inhibitors is key to optimizing their therapeutic use.